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Abstract
Background: Large-scale cohort-based whole exome sequencing of individuals with neurodevelopmental disorders
(NDDs) has identified numerous novel candidate disease genes; however, detailed phenotypic information is often
lacking in such studies. De novo mutations in pogo transposable element with zinc finger domain (POGZ) have
been identified in six independent and diverse cohorts of individuals with NDDs ranging from autism spectrum
disorder to developmental delay.
Methods: Whole exome sequencing was performed on five unrelated individuals. Sanger sequencing was used
to validate variants and segregate mutations with the phenotype in available family members.
Results: We identified heterozygous truncating mutations in POGZ in five unrelated individuals, which were
confirmed to be de novo or not present in available parental samples. Careful review of the phenotypes revealed
shared features that included developmental delay, intellectual disability, hypotonia, behavioral abnormalities, and
similar facial characteristics. Variable features included short stature, microcephaly, strabismus and hearing loss.
Conclusions: While POGZ has been associated with neurodevelopmental disorders in large cohort studies, our data
suggest that loss of function variants in POGZ lead to an identifiable syndrome of NDD with specific phenotypic traits.
This study exemplifies the era of human reverse clinical genomics ushered in by large disease-directed cohort studies;
first defining a new syndrome molecularly and, only subsequently, phenotypically.
Background
Neurodevelopmental disorders (NDDs) reflect a molecu-
larly and phenotypically heterogeneous classification
encompassing intellectual disability (ID), microcephaly,
and neurobehavioral traits such as autism spectrum
disorder (ASD) [1]. Collectively, these traits are quite
common, with ASD having a prevalence of ~1 % and ID
occurring in ~2–3 % of the population. The delineation
of various NDDs is not discrete, as more than one
phenotype is often present in an individual. Whole
exome sequencing (WES) has revealed that mutations
in the same gene may be associated with a broad
spectrum of neurobehavioral and neurodevelopmental
phenotypes [2, 3].
The clinical and genetic heterogeneity of ASD and
other neurobehavioral traits represents a challenge for
both molecular diagnoses and new gene discovery [4].
ASD is characterized by impairment in social interaction
as well as restricted and stereotyped patterns of interest
and activities, and is often accompanied by ID and
language delay. Recent advances in personal genome
analysis and the assembly of large cohorts for study have
begun to identify potentially pathogenic variants in
individuals with ASD; however, the majority of ASD loci
have yet to be identified and may include gene-
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regulatory mechanisms such as epigenetic modifications
and noncoding RNAs [1]. There is emerging evidence
for shared genomic underpinnings and genetic etiologies
of neuropsychiatric disorders, including ASD, schizo-
phrenia and ID, as evidenced by both WES studies [5]
and the mirror trait manifestations of some copy num-
ber variants (CNVs) [6].
The over-representation of de novo mutations in af-
fected individuals illustrates the strong genetic basis for
NDDs [5, 7, 8]. The prevalence of de novo CNVs has
been extensively explored during the past decade, with a
large proportion of ASD cases containing these events
[9–12]. Moreover, cognitive phenotypes have been tied
to CNV in population cohorts [6, 13]. However, despite
the known molecular etiology for ~20–30 % of cases,
the genetic etiology in the majority of individuals with
ASD is presently unable to be identified.
Genomic approaches to diagnosis include array com-
parative genomic hybridization (aCGH), whole genome
sequencing (WGS) and WES. These approaches have
identified the genetic etiology of many diverse Mendelian
diseases [14]. Recently, large-scale WES studies have been
conducted on a number of NDD cohorts [15–20]. These
studies have identified many likely pathogenic single
nucleotide variants, resulting in the generation of candi-
date gene lists for neurodevelopmental traits. However,
the large number of individuals in cohort publications pre-
cludes the reporting of detailed clinical information for
each case and often diagnostically relevant dysmorphology
is not recognized until a cohort of individuals with a
shared genetic etiology is assembled.
Premature truncating mutations in pogo transposable
element with zinc finger domain, or POGZ (MIM#614787),
have been implicated by WES in three ASD cohort studies
[16–18], cohorts examining developmental delay (DD) and
ID [15, 16] and one schizophrenia cohort [20]. Add-
itionally, a recently published case report details a
missense POGZ mutation present in an individual
with microcephaly, ASD, ID, and other clinical fea-
tures [21]. The recurrent identification of POGZ in
these studies has robustly implicated POGZ in diverse
NDDs, yet no thorough clinical analysis for POGZ
variant-associated phenotypic features has been pub-
lished to date.
Although relatively little is known about the function
of POGZ, a recent study detailed the interaction of the
zinc finger domain of POGZ with HP1α and the result-
ant activation of Aurora B kinase [22]. Therefore, POGZ
likely plays a role in mitotic progression through hetero-
chromatin formation and chromosomal segregation, and
may also influence gene expression. These functions of
POGZ are consistent with the presence of deleterious
variants in patients with microcephaly and other neuro-
developmental phenotypes [1].
We have identified five POGZ disrupting mutations in
patients with diverse clinical assessments. These individ-
uals have variable NDDs with shared features comprising
ID, global DD, behavioral abnormalities, microcephaly,
short stature, strabismus, and shared facial characteristics.
Together with eight pathogenic mutations from the litera-
ture, we describe the spectrum of phenotypes in individ-
uals with deleterious mutations in POGZ. Ascertainment
of patients with a shared molecular diagnosis and subse-
quent phenotypic characterization delineates the clinical
presentation common to individuals with POGZ muta-
tions. This genotype-driven approach may be especially
relevant for the variable presentations of NDDs, and can
be used to further clinically characterize candidate genes
identified in diverse cohort studies.
Methods
This study conforms to the Helsinki Declaration and was
performed with approval by the Baylor College of Medi-
cine institutional review board, protocol number H-29697,
for all sequencing conducted at the Baylor College of
Medicine Human Sequencing Center. Written informed
consent was obtained from the parents/legal guardians of
the patients for publication of this research and any ac-
companying images. Exome sequence analysis across all
sequencing centers followed the guidelines and process
for classifying sequencing variants developed by the
American College of Medical Genetics and Genomics
[23]. Trio-based sequencing allowed for the prioritization
of de novo loss-of-function mutations in four patients. An
average of 2.5 de novo mutations were identified in each
proband, of which POGZ was the only truncating allele.
Additionally, variants in POGZ were selected for confirm-
ation and co-segregation with the phenotype because loss-
of-function mutations in this gene have been found in
large cohorts of individuals with neuropsychiatric pheno-
types. All identified variants in POGZ have been deposited
into ClinVar under accession numbers SCV000256903,
SCV000256904, SCV000256905, SCV000256906, and
SCV000256907 in agreement with institutional review
board approval and patient consent.
DNA from patient 1 and her mother was subjected to
WES at the BCM Human Genome Sequencing Center
through the Baylor-Hopkins Center for Mendelian Gen-
omics initiative. Exome sequencing and analysis were per-
formed according to previously described methods [24].
Potential de novo mutations were identified in silico by
subtracting variants observed in the mother from those
observed in patient 1. Candidate variants were filtered
against exome data in publicly available databases, includ-
ing the 1000 Genomes Project, the National Heart, Lung,
and Blood Institute Exome Sequencing Project (ESP), the
Atherosclerosis Risk in Communities Study (ARIC)
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database (http://www2.cscc.unc.edu/aric), and our in-
house-generated database of approximately 5000 exomes.
Patients 2 and 3 were identified through diagnostic
WES at the Baylor-Miraca Medical Genetics Labora-
tory. Sequencing and data analysis were conducted as
previously described [25]. Briefly, the average coverage
for ~20,000 targeted genes (42 Mb of targeted re-
gions, including untranslated exons) was greater than
100×, and more than 95 % of the target bases were
covered by at least 20 reads [26].
Patients 4 and 5 were identified via diagnostic exome
sequencing at Ambry Genetics (Aliso Viejo, CA, USA).
Sequencing and data analysis at Ambry Genetics were
conducted as previously described [27]. The mean cover-
age across the parent–proband trio of patient 4 and
patient 5 was greater than 90× with >91 % of the tar-
geted bases covered at >20× .
PCR amplification and Sanger sequencing to verify all
candidate mutations were done according to standard
procedures and candidate variants were annotated using
the POGZ RefSeq transcript NM_015100.3. Parental




Characteristic clinical findings are summarized in Table 1.
Patient 1 is a 15-year-old female who initially pre-
sented in infancy with global DD. She walked at
17 months and her first words were at 18 months. She
had a developmental assessment done at 5 years
8 months of age, at which time her motor skills were at
age level with a performance IQ of 70, overall IQ of 50,
and full scale IQ of 56. Behavioral abnormalities were
apparent before 2 years of age, and as she developed, her
psychiatric symptoms became more pronounced and
included aggressive behavior, self-injury and property de-
struction that necessitated multiple inpatient psychiatric
admissions. Other medical issues included a disturbed
sleep cycle that responded to melatonin, mild obstruct-
ive sleep apnea, early-onset obesity, and mild myopia.
On physical examination at 15 years, her weight was
80.7 kg (97th percentile), height was 152 cm (6th per-
centile), and head circumference was 52.1 cm (−2 stand-
ard deviations). Her body mass index was 34.9 kg/m2
(99th percentile). Facial characteristics include brachy-
cephaly, a long and flat malar region, broad and de-
pressed nasal tip, short philtrum, thin vermillion border,
downturned corners of the mouth and pointed chin. She
had generalized hypotonia with a mildly wide-based and
waddling gait. Brain magnetic resonance imaging (MRI),
electroencephalogram, and audiology were normal. She
was initially suspected to have Smith-Magenis syndrome
due to sleep disturbance and global DD but high-density
aCGH for chromosome 17p11.2 was normal. Molecular
testing revealed a novel missense variant in RAI1
(NM_030665.3,c.4103A>G, p.S1212G) [28]. This variant
was predicted to be benign and polymorphic by
PolyPhen-2 and MutationTaster, and is poorly conserved
in mammalian evolution. However, the variant was
inherited from her father who had a history of learning
disability and a personality disorder, and is shared with
her sister who had clinical features suggestive of Smith-
Magenis syndrome [28]. Thus, we could not conclusively
rule out that this missense variant in RAI1 is contribut-
ing to the phenotype present in patient 1, but her more
severe developmental disability compared with her
father and sister warranted further work-up. Additional
diagnostic evaluation was noncontributory and included
chromosome analysis, fluorescent in situ hybridization
(FISH) for 22q11.2 deletion, MECP2 sequencing, fragile
X testing, lead levels, thyroid function studies, plasma
amino acids and urine organic acids. Due to the equivo-
cal interpretation of the RAI1 variant, research exome
sequencing was undertaken.
Patient 2 is a 31-month-old female with microcephaly,
short stature, global DD, non-ocular visual impairment,
failure to thrive and multiple congenital abnormalities,
including diaphragmatic hernia and a duplicated renal
collecting system. Initial echocardiogram showed a
patent ductus arteriosus and a patent foramen ovale or
atrial septal defect, which resolved without surgical
intervention. Physical examination revealed brachyceph-
aly, sparse hair, low-set and posteriorly rotated ears, long
malar region, hypertelorism with downslanting palpebral
fissures, a flat nasal bridge, with a broad and depressed
nasal tip, short philtrum, thin vermillion border, down-
turned corners of the mouth, pointed chin, and a short
neck with mild webbing. A full psychological and devel-
opmental assessment was performed at two years of age.
According to the Mullen Scales of Early Learning her
visual reception was within the 20th percentile, fine
motor was within the 20th percentile, receptive language
was within the 20th percentile, and expressive language
was within the 20th percentile. According to the Vine-
land adaptive behavior scales her communication skills
were below the first percentile, daily living skills were
below the first percentile, socialization was within the
first percentile, motor skills were below the first percent-
ile, and adaptive behavior were below the first percentile.
Collectively, the results of her formal assessment indi-
cate significant delays across all areas with relative weak-
ness in expressive language skills. Brain MRI showed
nonspecific delayed myelination and diffuse T2 hyperin-
tensity. Skeletal anomalies included multiple Wormian
bones and mild hypoplasia of the cervical vertebral bod-
ies. Previous work-up included chromosome analysis
and aCGH which were normal as well as very long chain
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Table 1 Phenotypic and molecular data
Patient ID 1a 2 3 4 5 Patients reported
in literature (8)
Genotype c.2321_2324delCTCT c.2763dupC c.833C > G c.2935C > T c.2780dupT
Effect p.Ser774Cysfs*16 p.Thr922Hisfs*22 p.Ser278* p.Arg979* p.Leu927Phefs*17 Frameshift or
stopgain (7);
missense (1)
Exon number Exon 15 (CDS 14) Exon 19 (CDS 18) Exon 6 (CDS 5) Exon 19
(CDS 18)
Exon 19 (CDS 18)
De novo Not maternal + + + + 8/8
Age at evaluation 15 years 19 months 3 years
10 months
5 years 4 years 7 months
Gender F F M F F M (3); F (2); NR (3)
Paternal age NA 45 years 28 years NA 30 years
DD/ID + + + + + + (7); NR (1)
Behavioral
phenotype
+ + + NA +




Hearing loss - SNHL NA SNHL SNHL + (1); NR (7)









Seizures - - Complex
partial seizures
- - 1 (with hypoglycemia);
NR (7)
GI manifestations NA + + + +
Stature <10th
percentile
+ + - + + + (1); NR (7)
Microcephaly - + - + + + (2); NR (6)
Brachycephaly + + - + +
Midface hypoplasia + - - + +
Strabismus - + + + + + (1); NR (7)
Optic nerve
hypoplasia
- - - + +
Long and flat malar
region
+ + + + -
Flat nasal bridge + + - - +
Broad nasal tip + + + + +
Short philtrum + + + + +
Thin vermillion
border
+ + + - +
Downturned corners
of the mouth
+ + + + +











- + (1; abnormal
outer ear); NR (7)
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fatty acids. A clinical concern for Pallister-Killian was
entertained at birth due to facial features and congenital
diaphragmatic hernia.
Patient 3 is a 3-year 10-month-old male with global
DD, complex partial seizures and behavioral abnormal-
ities concerning for ASD. He first presented at two
months of age due to poor weight gain and poor suck
and latch. At 34 months of age, DAYC-2 formal develop-
mental assessment was administered and he scored a
General Developmental Index of 67, interpreted as sig-
nificantly below age-level across all areas. His full scale
IQ at 34 months was 71 (third percentile), verbal com-
prehension was 85 (14th percentile) and non-verbal abil-
ities were 64 (first percentile). Physical examination
revealed strabismus, bifid uvula, a wide space between
the central incisors, brachydactyly, large thumbs, broad
feet, and large toes. Ophthalmology exam at 12 months
of age detected hyperopia and astigmatism. Family his-
tory was significant for seizures on the maternal side. He
has complex partial seizures localizing to the left fronto-
parietal area. He was initially treated with phenobarbital
but switched to levetiracetam and was well-controlled.
Due to concern that this drug was contributing to his
behavioral issues, the patient was switched to oxcarbaze-
pine. He developed tic-like movements after the second
dose and it was stopped. Topiramate was added and he
did start having new seizures while he was on both
topiramate and levetiracetam but controlled with higher
doses of topiramate. Levetiracetam was eventually
weaned and the irritability has improved. Previous work-
up was unrevealing and included chromosome analysis,
aCGH, metabolic testing, Angelman methylation studies
and CREBBP and EP300 testing for Rubinstein-Taybi
syndrome I and II.
Patient 4 is a 5-year-old female with microcephaly,
short stature, global DD, and a history of low muscle
tone. Additional medical concerns included feeding diffi-
culties, severe gastroesophageal reflux disease, sensori-
neural hearing loss, exotropia, and obstructive sleep
apnea. Facial characteristics included brachycephaly, a
sloping broad forehead, posteriorly rotated ears, upslant-
ing palpebral fissures, long and flat malar region, broad
and depressed nasal tip, short philtrum, downturned
corners of the mouth, high palate, pointed chin, and
relative prognathia. Ophthalmology exam showed exotro-
pia, anisometropia, optic nerve hypoplasia, and rod-cone
retinal dystrophy. Brain MRI showed optic nerve hypopla-
sia with no other structural abnormalities. Skeletal survey
was normal other than significant brachycephaly. At age
27 months she underwent a developmental assessment.
According to both the Clinical and Auditory Milestones
Scale and Cognitive adaptive test she scored at a basal
level of 6 months, indicating severe delays across all areas
of development with most significant delays to her acqui-
sition of speech and language. Previous molecular testing
included aCGH, which revealed a paternally inherited
125-kb copy number gain within chromosome 12q24.12;
she had a normal chromosome analysis, an unrevealing
targeted microcephaly gene panel, and normal thyroid
function studies, plasma amino acids, urine organic acids,
and urine mucopolysaccharides.
Patient 5 is a 4-year 7-month-old female with micro-
cephaly, cleft palate, global DD, hypotonia and ASD. She
presented at birth with cleft palate, micrognathia and a
Table 1 Phenotypic and molecular data (Continued)
Micrognathia - - - - + (infancy)
Prognathism + - - + + (toddler)
Short neck + + - - -
Brachydactyly - - + - +
Joint laxity + + - - -
Hypotonia + + + - + + (1); NR (7)
























- - PFO; left duplicated
renal collecting
system
Abbreviations: ASD atrial septal defect, GI gastrointestinal, F female, M male, MRI magnetic resonance imaging, NA not available, NR not reported, PDA patent
ductus arteriosus, PFO patent foramen ovale, SNHL sensorineural hearing loss
aPatient 1 was previously reported as patient 2 in Bi et al. [28]
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duplicated renal collecting system. Facial and physical
characteristics included broad forehead, brachycephaly,
broad and depressed nasal tip, short philtrum, thin ver-
million border, downturned corners of the mouth,
pointed chin, and small hands with relative brachydac-
tyly. Upon her initial clinical presentation additional
features were noted, including auditory neuropathy,
immune deficiency, and left duplicated renal collecting
system. Ophthalmology exam showed exotropia, astig-
matism and small optic nerves. Brain MRI revealed
Dandy-Walker variant, decreased white matter, and
enlarged third and fourth ventricles. Her original exome
report identified compound heterozygous variants of
unknown clinical significance in STIL, associated with
primary microcephaly. Additionally, microarray revealed
a paternally inherited Xq21.1 duplication. Previous normal
testing included chromosome analysis, FISH for 22q11
deletion, methylation studies for Prader Willi and
Angelman syndromes, and ROR2 sequencing. Other test-
ing, all normal, included urine organic acids, serum amino
acids, acylcarnitine, and very long chain fatty acids.
Phenotypic spectrum
The clinical description of the individuals in this study
overlaps with the descriptions of previously reported pa-
tients [15–20]. All five subjects had global DD and/or
ID. Behavioral abnormalities ranged from self-injurious
behavior to high-functioning ASD. Additional common
features included microcephaly (3/5), stature below the
tenth percentile (4/5), hypotonia (4/5), strabismus (4/5),
vision abnormalities (5/5), sensorineural hearing loss
(3/5), and gastrointestinal manifestations including
poor feeding, gastroesophageal reflux, and/or consti-
pation (4/5). Recurrent facial and physical characteris-
tics included hypotonic facies with an open mouth,
brachycephaly (4/5), long and flat malar region (4/5),
posteriorly rotated ears (2/5), broad nasal tip (5/5),
flat nasal bridge (3/5), short philtrum (5/5), thin ver-
million border (4/5), downturned corners of the
mouth (4/5), high arched palate (3/5), and pointed
chin (4/5). An overview of clinical features is pre-
sented in Table 1. Pictures of the five patients are
shown in Fig. 1.
Genomic analyses
To date, seven de novo mutations leading to prema-
ture termination of POGZ have been identified in co-
horts of individuals with diverse NDDs, including
ASD (N = 3), ID (N = 6), DD (N = 2), or schizophrenia
(N = 1) [15–20]. The truncating variants result in termin-
ation of the protein prior to or within the C-terminal DDE
and/or coiled-coil domains. Additionally, a de novo mis-
sense mutation in the CENP-B like DNA binding domain
of POGZ was also reported in a child with ASD, ID and
dysmorphic features (Fig. 2) [21].
We identified five patients with heterozygous truncat-
ing mutations in POGZ. Four of the five variants were
confirmed to be de novo in the affected individual; the
father of patient 1 was unavailable for analysis but his
mother did not harbor the POGZ variant. Extensive
testing for each of these individuals was negative, with
the exception of a paternally inherited missense variant
in RAI1 in patient 1 of uncertain clinical significance
[28] and compound heterozygous variants of uncertain
clinical significance in STIL in patient 5. We identified
heterozygous truncating variants in POGZ in all five
individuals by WES; these five variants were validated by
Sanger sequencing (Fig. 2). Publicly available databases,
including ARIC and the Exome Aggregation Consortium
(ExAC; version 0.3; Cambridge, MA, USA; http://exac.
broadinstitute.org) confirmed that the identified variants
are unique to our patients. Table 2 provides a molecular
description of variants identified in these five patients
and eight previously identified cases. Indels resulting in
frameshift mutations were present in three of five pa-
tients and two of five contained nonsense mutations
(one transition and one transversion). Three of the five
variants occur in the final exon of POGZ and can poten-
tially escape nonsense-mediated decay. However, the two
patients with variants predicted to be subject to degrad-
ation by nonsense-mediated decay do not have distin-
guishing phenotypic features from the three terminal
exon-containing patients. All five truncating mutations
are predicted to result in the loss of greater than 402
amino acids at the C-terminus of POGZ. Loss of this re-
gion of the protein is predicted by conceptual translation
to result in deletion of the CENP-B like DNA binding
domain, the DDE domain and the coiled-coil domain.
Thus, the mutations present in each of the five individ-
uals in this study likely result in loss of function. The
assertion that heterozygous loss of function mutations in
POGZ cause diverse NDDs is further supported by the
presence of two CNVs encompassing POGZ coding
regions in the DECIPHER database [29]. The two indi-
viduals with small deletions of POGZ are phenotypically
described as having DD and additional significant devel-
opmental and morphological phenotypes.
Discussion
Large cohort studies have associated truncating muta-
tions in POGZ with behavioral abnormalities, ID, and
DD [16–21]. The identification of numerous candidate
genes in these studies highlights their value. However, to
thoroughly describe the clinically relevant phenotypes
associated with mutation in a given gene, targeted ana-
lyses of a molecularly defined cohort are required. Here,
we utilized a genotype-first approach to identify shared
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facial and physical characteristics as well as the spectrum
of individual phenotypes resulting from deleterious
mutations in POGZ.
We identified five patients with novel truncating muta-
tions in POGZ, likely resulting in loss-of-function alleles.
The description of the five individuals and a review of
eight patients from the literature indicate that individ-
uals with mutations in POGZ are likely to have global
DD, microcephaly, ID, strabismus and variable hearing
loss. Comparison of facial and physical characteristics in
our five subjects has revealed shared facial features, in-
cluding brachycephaly, long and flat malar region, broad
nasal tip, short philtrum, thin vermillion border, down-
turned corners of the mouth and pointed chin (Fig. 1).
Patients also present with highly variable neurobehav-
ioral phenotypes, ranging from ASD to severe aggressive
behaviors similar to what is seen in individuals with
Smith-Magenis syndrome (Table 1).
It is possible that patient 1 and patient 2 may have a
blended phenotype; patient 1 has a paternally inherited
missense mutation in RAI1, which is associated with
Smith-Magenis syndrome. In addition to the characteris-
tic features, patient 2 also presented with congenital
abnormalities, including diaphragmatic hernia, a renal
tract anomaly, and heart defects. Other than the de novo
POGZ mutation, we did not identify additional molecu-
lar events that would account for her phenotype. There-
fore, although it is possible that POGZ truncating
mutations could lead to clinical phenotypes including
mild congenital abnormalities, an additional unidenti-
fied cause in patient 2 could potentially be respon-
sible for her uncharacteristic presentations. Together,
our data and a literature review indicate that dam-
aging variants in POGZ result in a broad range of
features distinguished by global DD, ID, neurobehavioral
abnormalities (most often ASD), short stature, hypotonia,
Fig. 1 Photographs of patients displaying common facial features. Shared facial dysmorphology among affected individuals includes brachycephaly,
long and flat malar region, broad and depressed nasal tip, short philtrum, thin vermillion border, downturned corners of the mouth and pointed chin
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Fig. 2 Locations and chromatograms of variants identified. a The functional protein domains of POGZ. Functional protein domains include zinc-finger domains (orange and yellow), a
predicted proline-rich domain (red), CENP-B like DNA binding domain (green), DDE transposase domain (blue) and a coiled-coil domain (purple). The seven truncating mutations and one
deleterious missense previously reported are indicated by stars above the predicted domains. b Truncating mutations identified in the current study are indicated at their respective














strabismus, characteristic facial features, including brachy-
cephaly, long and flat malar region, broad nasal tip, short
philtrum, thin vermillion border, downturned corners of
the mouth, and pointed chin, and variable hearing loss.
POGZ has not been extensively characterized; the pro-
tein product contains eight canonical C2H2-like zinc fin-
ger domains that are implicated in protein–protein
interactions and have the potential for DNA interactions
[30]. The C-terminus of the protein contains a B-like
centromere binding domain and a DDE domain (Fig. 2).
Interestingly, POGZ interacts with HP1α via the zinc
finger domain; this activates Aurora B kinase, indicating
a potential role for POGZ in mitotic progression and
neuronal differentiation [22]. Similar to POGZ, many
genes encoding proteins required for proper centroso-
mal function or chromosome segregation are mutated
in patients with microcephaly, demonstrating a com-
mon theme of aberrant neuronal proliferation and
migration [1, 31].
POGZ is expressed in developing cortical projection
neurons which have been implicated in a network con-
vergence of neurodevelopmental risk genes [32]. HP1α
also strongly interacts with NIPBL, which is mutated in
individuals with Cornelia de Lange syndrome. The over-
lapping molecular networks of POGZ and NIPBL may
indicate common mechanisms of transcriptional dysreg-
ulation with deleterious mutation of these genes [24].
Although NDDs are typically a clinical diagnosis, mo-
lecular genetic testing, including both aCGH and WES,
is capable of more precisely defining syndromes and dis-
orders with highly variable phenotypes [33]. With the
expanding number of single-gene candidates for NDDs
and the variability of these phenotypes, WES was crucial
in defining the cohort of five patients presented here.
The increasing emergence of candidate genes for various
disorders necessitates genotype-driven approaches for
describing associated phenotypic spectrums. Further-
more, with a better understanding of the clinical presen-
tations of patients with deleterious POGZ mutations,
more molecular diagnoses may be forthcoming.
Conclusions
We report the detailed phenotypic features associated
with loss of function variants in POGZ. These include a
broad range of features distinguished by global DD,
microcephaly, ID, neurobehavioral abnormalities (in-
cluding ASD), short stature, hypotonia, strabismus and
variable hearing loss. We also describe characteristic
facial features of this disorder that include brachyceph-
aly, long and flat malar region, broad nasal tip, short
philtrum, thin vermillion border, downturned corners of
the mouth, and pointed chin. Identification of POGZ
variants and subsequent description of characteristic
clinical presentations demonstrate the utility of human
reverse genetics in an era of personal genome analyses
and clinical genomics.
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